Inhibikase Therapeutics (IKT) Short-term Investments (2022 - 2026)
Inhibikase Therapeutics (IKT) posted Short-term Investments of $127.81 million for Q2 2026, compared with $9.92 million a year earlier and up 5.8% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Short-term Investments (2022 - 2026) Analysis & Trends
At the end of FY2025, Inhibikase Therapeutics' Short-term Investments came in at $39.54 million, down 3.7% from FY2024.
- Annual Short-term Investments shows a three-year compound annual growth rate of 35.6% (FY2022 to FY2025).
- In prior years, Inhibikase Therapeutics' Short-term Investments was $41.05 million in FY2024 (+904.5%), $4.09 million in FY2023 (-74.2%) and $15.86 million in FY2022.
- The Q2 2026 figure stands as the highest quarterly Short-term Investments in data going back to Q3 2022.
- On a year-over-year basis, Short-term Investments increased in five of the last six quarters, with growth averaging 283.7%.
- The strongest year-over-year quarter for Short-term Investments in the past five years was Q4 2024, with growth of 904.5%; the weakest was Q3 2023, with a decline of 90.5%.
- According to Business Quant data, Short-term Investments for the three prior quarters was $120.8 million (Q1 2026), $39.54 million (Q4 2025) and $39.05 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn |
| 10 | Inhibikase Therapeutics | 349.14 Mn | -236.33 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 127.81 Mn |
| Mar 31, 2026 | 120.80 Mn |
| Dec 31, 2025 | 39.54 Mn |
| Sep 30, 2025 | 39.05 Mn |
| Jun 30, 2025 | 9.92 Mn |
| Mar 31, 2025 | 19.74 Mn |
| Dec 31, 2024 | 41.05 Mn |
| Sep 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 4.85 Mn |
| Mar 31, 2024 | 7.40 Mn |
| Dec 31, 2023 | 4.09 Mn |
| Sep 30, 2023 | 1.97 Mn |
| Jun 30, 2023 | 19.03 Mn |
| Mar 31, 2023 | 21.76 Mn |
| Dec 31, 2022 | 15.86 Mn |
| Sep 30, 2022 | 20.75 Mn |
API Access
Inhibikase Therapeutics Short-term Investments API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=short-term-investments&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "short-term-investments", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=short-term-investments&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();